G. Fine

发表

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

R. Bourgon, P. Hegde, Yulei N. Wang, 2018, Nature.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

R. Bourgon, P. Hegde, T. Powles, 2017, The Lancet.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

R. Bourgon, T. Powles, M. Galsky, 2016, The Lancet.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

P. Hegde, T. Powles, H. Burris, 2014, Nature.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

H. Kohrt, P. Hegde, R. Herbst, 2014, Nature.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

J. Reeves, P. Hegde, A. Ravaud, 2018, Nature Medicine.

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.

R. Gascoyne, L. Sehn, M. Crump, 2012, Blood.

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

L. Sehn, G. Gaidano, G. Martinelli, 2017, Leukemia & lymphoma.

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

R. Herbst, S. Gettinger, J. Soria, 2013 .

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).

T. Powles, J. Sosman, M. Sznol, 2013 .

Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).

P. Hegde, T. Powles, H. Koeppen, 2014 .

Perspective of clinical research in follicular NHL: interaction between science and industry.

S. Horning, G. Fine, 2011, Best practice & research. Clinical haematology.

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

J. Sosman, F. Hodi, S. Gettinger, 2013 .

CD4 ligand IL-16 inhibits the mixed lymphocyte reaction.

G. Fine, A. Theodore, W. Cruikshank, 1996, Journal of immunology.

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

J. Wolchok, T. Powles, F. Hodi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.

H. Kohrt, J. Tabernero, Daniel S Chen, 2013 .

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

Jaegil Kim, G. Demetri, S. Grupp, 2022, Nature Communications.

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

P. Hegde, H. Koeppen, J. Bruey, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation.

G. Fine, A. Theodore, P. Weller, 1996, Journal of immunology.

Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients.

G. Fine, J. Saukkonen, W. Cruikshank, 1998, The Journal of allergy and clinical immunology.

Tumor necrosis factor-alpha-induced synthesis of interleukin-16 in airway epithelial cells: priming for serotonin stimulation.

G. Fine, W. Cruikshank, F. Little, 2003, American Journal of Respiratory Cell and Molecular Biology.

Association of PD-L2 expression in human tumors with atezolizumab activity.

P. Hegde, T. Powles, F. Hodi, 2016 .

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

J. Reeves, P. Hegde, A. Ravaud, 2018, Nature Medicine.

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

P. Hegde, T. Powles, J. Sosman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

808OINHIBITION OF PD-L1 BY MPDL3280A LEADS TO CLINICAL ACTIVITY IN PTS WITH METASTATIC UROTHELIAL BLADDER CANCER (UBC).

P. Hegde, T. Powles, H. Burris, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

J. Sosman, R. Herbst, F. Hodi, 2013 .

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

A. Italiano, J. Soria, A. Mcdonald, 2015 .

Immune-Modi fi ed Response Evaluation Criteria In Solid Tumors ( imRECIST ) : Re fi ning Guidelines to Assess the Clinical Bene fi t of Cancer Immunotherapy

J. Wolchok, T. Powles, F. Hodi, 2018 .

A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).

A. Ravaud, J. Hainsworth, R. Motzer, 2017 .

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

J. Reeves, P. Hegde, A. Ravaud, 2018, Nature Medicine.

Abstract 2941: Local tumor irradiation combined with α-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series

H. Kohrt, D. Czerwinski, G. Fine, 2014 .

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

S. Armstrong, H. Döhner, R. Koche, 2015 .

Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

F. Hodi, G. Fine, O. Hamid, 2013 .

809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

T. Powles, J. Sosman, M. Sznol, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

P. Hegde, T. Powles, H. Burris, 2014, Nature.

Perspective of clinical research in follicular NHL: interaction between science and industry.

S. Horning, G. Fine, 2011, Best practice & research. Clinical haematology.

Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab

P. Hegde, H. Koeppen, J. Bruey, 2016 .

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (UBC)

P. Hegde, T. Powles, D. Petrylak, 2014 .

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

P. Hegde, T. Powles, D. Petrylak, 2014, Journal of Immunotherapy for Cancer.

Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitnib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients

P. Hegde, R. Motzer, T. Powles, 2017 .